Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
24
pubmed:dateCreated
2005-12-16
pubmed:abstractText
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a small molecule in the flavanoid class that has antitumor activity thought to be due to ability to induce high local levels of tumor necrosis factor (TNF)-alpha that disrupt established blood vessels within tumors. The drug has completed phase 1 testing in humans and is currently in phase 2 trials in combination with chemotherapy. Although characterized as a "vascular disrupting agent," there are some studies suggesting that DMXAA also has effects on the immune system that are important for its efficacy. The goal of this study was to carefully define the immune effects of DMXAA in a series of murine lung cancer and mesothelioma cell lines with varying immunologic characteristics. We show that DMXAA efficiently activated tumor-associated macrophages to release a variety of immunostimulatory cytokines and chemokines, including TNF-alpha; IFN-inducible protein-10; interleukin-6; macrophage inflammatory protein-2; monocyte chemotactic protein-1; and regulated on activation, normal T-cell expressed, and secreted. DMXAA treatment was highly effective in both small and large flank tumors. Animals cured of tumors by DMXAA generated a systemic memory response and were resistant to tumor cell rechallenge. DMXAA treatment led to initial tumor infiltration with macrophages that was followed by an influx of CD8(+) T cells. These CD8(+) T cells were required for antitumor efficacy because tumor inhibitory activity was lost in nude mice, mice depleted of CD8(+) T cells, and perforin knockout mice, but not in CD4(+) T-cell-depleted mice. These data show that activation of tumor-associated macrophages by DMXAA is an efficient way to generate a CD8(+) T-cell-dependent antitumor immune response even in animals with relatively nonimmunogenic tumors. Given these properties, DMXAA might also be useful in boosting other forms of immunotherapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
11752-61
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16357188-Angiogenesis Inhibitors, pubmed-meshheading:16357188-Animals, pubmed-meshheading:16357188-Antineoplastic Agents, pubmed-meshheading:16357188-CD4-Positive T-Lymphocytes, pubmed-meshheading:16357188-CD8-Positive T-Lymphocytes, pubmed-meshheading:16357188-Carcinoma, Lewis Lung, pubmed-meshheading:16357188-Chemokines, pubmed-meshheading:16357188-Cytokines, pubmed-meshheading:16357188-Disease Models, Animal, pubmed-meshheading:16357188-Immunotherapy, pubmed-meshheading:16357188-Lung Neoplasms, pubmed-meshheading:16357188-Macrophages, pubmed-meshheading:16357188-Membrane Glycoproteins, pubmed-meshheading:16357188-Mesothelioma, pubmed-meshheading:16357188-Mice, pubmed-meshheading:16357188-Mice, Inbred BALB C, pubmed-meshheading:16357188-Mice, Inbred C57BL, pubmed-meshheading:16357188-Mice, Knockout, pubmed-meshheading:16357188-Mice, Nude, pubmed-meshheading:16357188-Neovascularization, Pathologic, pubmed-meshheading:16357188-Perforin, pubmed-meshheading:16357188-Pore Forming Cytotoxic Proteins, pubmed-meshheading:16357188-Xanthones
pubmed:year
2005
pubmed:articleTitle
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
pubmed:affiliation
Thoracic Oncology Research Laboratory, University of Pennsylvania Medical School, Philadelphia, 19104, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural